Development

Articles

UCR scientists are researching whether a plant-based messenger RNA vaccine can be created and aim to eliminate the need for the refrigeration of mRNA vaccines during transport and storage.

Researchers from the University of California Riverside Investigate Plant-Based mRNA Vaccines

Moderna announced a collaboration to develop a new mRNA therapeutic for Crigler-Najjar Syndrome Type 1 at no cost to patients.

Moderna and ILCM Announce Collaboration to Develop mRNA Therapeutic for CN-1

FSD Pharma has entered a definitive agreement to acquire all of the issued and outstanding shares of Lucid Psycheceuticals for approximately US$9 million (CAD$11.3 million) in FSD Pharma stock.

FSD Pharma to Acquire Lucid Psycheceuticals

FDA has cleared QSAM Biosciences’s IND application for Samarium-153 DOTMP (CycloSam).

Investigational Radiopharmaceutical for the Treatment of Bone Cancer Receives FDA Clearance of IND

Nanoform and Boehringer Ingelheim have executed a master services agreement in relation to pre-clinical development projects.

Nanoform, Boehringer Ingelheim Collaborate on Pre-Clinical Development Projects

A research collaboration will combine Imugene’s oncolytic virus technology with Celularity’s allogeneic CAR T-cell therapy.

Imugene and Celularity to Develop Solid Tumor Treatment

Ramesh Kumar is a graduate student at the Indian Institute of Technology, Delhi.

Manidipa Banerjee is a professor in the Kusuma School of Biological Sciences at the Indian Institute of Technology, Delhi.

Anurag S. Rathore is a professor in the Department of Chemical Engineering at the Indian Institute of Technology Delhi and a member of 

l's Editorial Advisory Board, Tel. +91.9650770650, asrathore@biotechcmz.com.

Analytical and functional characterization of virus-like particles enables process reproducibility and product consistency. 

Virus-like Particles as Therapeutic Moieties of the Future

Samsung Biologics has adopted Solentim’s cell seeding and cell metric platforms at its new R&D center in San Francisco, CA. 

Samsung Biologics Incorporates Solentim’s Cell Line Development Technology into New R&D Center 

Feliza Mirasol is the science editor for 

Bio/Pharma companies are galvanized to develop COVID-19 therapies under FDA’s acceleration program.

Bio/Pharma Industry Works Overtime to Find COVID-19 Therapies

Narendra Chirmule, PhD, is CEO at SymphonyTech Biologics.

Himanshu Malani is a graduate student at the Indian Institute of Technology, Delhi.

Advances in preclinical development play a crucial role in reducing cost for developing biosimilars.

Early Phase Development